Marinus Pharmaceuticals (NASDAQ: MRNS) and Immune Pharmaceuticals (NASDAQ:IMNP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk and profitability.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Marinus Pharmaceuticals and Immune Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Marinus Pharmaceuticals 0 0 1 0 3.00
Immune Pharmaceuticals 0 0 1 0 3.00

Marinus Pharmaceuticals presently has a consensus target price of $11.00, indicating a potential upside of 98.56%. Immune Pharmaceuticals has a consensus target price of $3.00, indicating a potential upside of 268.37%. Given Immune Pharmaceuticals’ higher possible upside, analysts plainly believe Immune Pharmaceuticals is more favorable than Marinus Pharmaceuticals.

Volatility & Risk

Marinus Pharmaceuticals has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. Comparatively, Immune Pharmaceuticals has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500.

Valuation & Earnings

This table compares Marinus Pharmaceuticals and Immune Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Marinus Pharmaceuticals N/A N/A -$22.16 million ($0.93) -5.96
Immune Pharmaceuticals N/A N/A -$12.48 million ($6.87) -0.12

Marinus Pharmaceuticals is trading at a lower price-to-earnings ratio than Immune Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Marinus Pharmaceuticals and Immune Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Marinus Pharmaceuticals N/A -106.20% -75.33%
Immune Pharmaceuticals N/A -552.76% -107.04%

Insider and Institutional Ownership

23.6% of Marinus Pharmaceuticals shares are held by institutional investors. Comparatively, 3.4% of Immune Pharmaceuticals shares are held by institutional investors. 6.4% of Marinus Pharmaceuticals shares are held by company insiders. Comparatively, 6.7% of Immune Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Marinus Pharmaceuticals beats Immune Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

Immune Pharmaceuticals Company Profile

Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.

Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.